Literature DB >> 18288568

B-Lymphoid and myeloid lineages biphenotypic acute leukemia with t(8;21)(q22;q22).

Guangsheng He1, Depei Wu2, Aining Sun1, Yongquan Xue1, Zhengming Jin1, Huiying Qiu1, Xiaowen Tang1, Miao Miao1, Zhengzheng Fu1, Xiao Ma1, Xiuli Wang1, Zixin Chen1, Changgeng Ruan1.   

Abstract

By analyzing the characteristics of morphology, immune phenotype, chromosome karyotype and clinical manifestations of six cases of B-lymphoid and myeloid lineages biphenotypic acute leukemia (BAL) with t(8;21)(q22;q22), a new subgroup of BAL was reported. Bone marrow eosinophilia (more than 5%) and pseudo-Chediak abnormalities were not found. Auer rods were also not identified in four of six cases. Immunophenotype revealed B-lymphoid and myeloid lineages positive, together with frequent and high expression of CD34 and CD33, and weak expression of HLA-DR. In addition to t(8;21) chromosomal translocation, deletion of Y chromosome and complex chromosome abnormalities were also found. Chemotherapy for myeloid and lymphoid leukemia simultaneously produced good response in the patients. BAL with t(8; 21)(q22; q22) might be a new subgroup of BAL, and it was suggested that the leukemia clone with t(8;21)(q22;q22) might have originated from an early phase of hematopoiesis, and AML1/ETO fusion gene might be related to differentiation of B lymphocyte.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18288568     DOI: 10.1007/s12185-008-0029-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  16 in total

1.  The promoter of the CD19 gene is a target for the B-cell-specific transcription factor BSAP.

Authors:  Z Kozmik; S Wang; P Dörfler; B Adams; M Busslinger
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter.

Authors:  T A Libermann; Z Pan; Y Akbarali; C J Hetherington; J Boltax; D A Yergeau; D E Zhang
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

3.  AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia.

Authors:  F Kuchenbauer; M Feuring-Buske; C Buske
Journal:  Cell Cycle       Date:  2005-12-14       Impact factor: 4.534

4.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

5.  Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression.

Authors:  O Legrand; J Y Perrot; G Simonin; M Baudard; M Cadiou; C Blanc; S Ramond; F Viguié; J P Marie; R Zittoun
Journal:  Br J Haematol       Date:  1998-01       Impact factor: 6.998

Review 6.  Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity.

Authors:  Felicetto Ferrara; Luigi Del Vecchio
Journal:  Haematologica       Date:  2002-03       Impact factor: 9.941

7.  AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation.

Authors:  T Miyamoto; I L Weissman; K Akashi
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

8.  Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter.

Authors:  D Fitzsimmons; W Hodsdon; W Wheat; S M Maira; B Wasylyk; J Hagman
Journal:  Genes Dev       Date:  1996-09-01       Impact factor: 11.361

9.  Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein.

Authors:  P Zwollo; S Desiderio
Journal:  J Biol Chem       Date:  1994-05-27       Impact factor: 5.157

10.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).

Authors:  M C Bene; G Castoldi; W Knapp; W D Ludwig; E Matutes; A Orfao; M B van't Veer
Journal:  Leukemia       Date:  1995-10       Impact factor: 11.528

View more
  4 in total

1.  Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population.

Authors:  Xiao-Qian Xu; Jian-Min Wang; Shu-Qing Lü; Li Chen; Jian-Min Yang; Wei-Ping Zhang; Xian-Min Song; Jun Hou; Xiong Ni; Hui-Ying Qiu
Journal:  Haematologica       Date:  2009-05-19       Impact factor: 9.941

2.  Diagnosis of biphenotypic acute leukemia: a paradigmatic approach.

Authors:  Xianfeng Frank Zhao; Ivana Gojo; Teresa York; Yi Ning; Maria R Baer
Journal:  Int J Clin Exp Pathol       Date:  2009-10-10

3.  The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype.

Authors:  V J Forster; M H Nahari; N Martinez-Soria; A K Bradburn; A Ptasinska; S A Assi; S E Fordham; H McNeil; C Bonifer; O Heidenreich; J M Allan
Journal:  Leukemia       Date:  2015-06-08       Impact factor: 11.528

4.  Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used.

Authors:  Alan Pomerantz; Sergio Rodriguez-Rodriguez; Roberta Demichelis-Gomez; Georgina Barrera-Lumbreras; Olga Barrales-Benitez; Xavier Lopez-Karpovitch; Alvaro Aguayo-Gonzalez
Journal:  Blood Res       Date:  2016-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.